C07D 277/593
Z being doubly bound oxygen or doubly bound nitrogen, which nitrogen is
Official title: Z being doubly bound oxygen or doubly bound nitrogen, which nitrogen is part of a possibly substituted oximino radical
C07D277/593 (Z being doubly bound oxygen or doubly bound nitrogen, which nitrogen is) appears on 24 US grants and 35 published applications in this corpus.
Search patents in C07D- Granted patents
- 24
- Published applications
- 35
- Assignees
- 22
- Inventors
- 74
- Latest grant
- 1 Apr 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2007 | 0 | 1 |
| 2008 | 0 | 1 |
| 2009 | 1 | 1 |
| 2010 | 0 | 0 |
| 2011 | 0 | 1 |
| 2012 | 1 | 2 |
| 2013 | 0 | 3 |
| 2014 | 2 | 4 |
| 2015 | 3 | 5 |
| 2016 | 1 | 1 |
| 2017 | 2 | 2 |
| 2018 | 4 | 4 |
| 2019 | 2 | 2 |
| 2020 | 1 | 1 |
| 2021 | 2 | 2 |
| 2022 | 2 | 2 |
| 2023 | 0 | 1 |
| 2024 | 1 | 0 |
| 2025 | 2 | 2 |
By publication year.
Recent patents
- Ribosome-mediated incorporation of peptides and peptidomimetics1 Apr 2025US 12,264,318 B2Arizona Board of Regents on behalf of Arizona State University
- Compounds as NLRP3 inflammasome inhibitors and compositions and uses thereof11 Feb 2025US 12,221,406 B2Virginia Commonwealth University
- Drug-conjugates, conjugation methods, and uses thereof15 Oct 2024US 12,115,228 B2Concortis Biosystems, Corp.
- Ribosome-mediated incorporation of peptides and peptidomimetics6 Sep 2022US 11,434,492 B2Arizona Board of Regents on behalf of Arizona State University
- (S)-n-hydroxy-2-(2-(4-methoxyphenyl)butanamido)thiazole-5-carboxamide and pharmaceutically acceptable salts thereof23 Aug 2022US 11,420,947 B2Translational Drug Development, LLC
- Ribosome-Mediated Incorporation of Peptides and Peptidomimetics19 Jun 2025US 2025/0197869 A1Arizona Board of Regents on behalf of Arizona State University
- Drug-Conjugates, Conjugation Methods, And Uses Thereof1 May 2025US 2025/0135024 A1Concortis Biosystems, Corp.
- Ribosome-Mediated Incorporation of Peptides and Peptidomimetics16 Feb 2023US 2023/0046194 A1Arizona Board of Regents on behalf of Arizona State University
- (s)-n-hydroxy-2-(2-(4-methoxyphenyl)butanamido)thiazole-5-carboxamide and pharmaceutically acceptable salts thereof22 Dec 2022US 2022/0402884 A1Translational Drug Development, LLC
- Compounds as nlrp3 inflammasome inhibitors and compositions and uses thereof18 Aug 2022US 2022/0259144 A1Virginia Commonwealth University
Most cited
By later US patents
- Inhibitors of histone deacetylase9US 8,673,911 B2MethylGene Inc. · 2014
- Drug-conjugates, conjugation methods, and uses thereof9US 9,801,951 B2Concortis Biosystems, Corp. · 2017
- Heterocyclic guanidine F1F0-atpase inhibitors and therapeutic uses thereof8US 9,221,814 B2Lycera Corporation · 2015
- Drug-conjugates, conjugation methods, and uses thereof3US 9,884,127 B2Concortis Biosystems, Corp. · 2018
- Epoxyeicosatrienoic acid analogs and methods of making and using the same2US 9,127,027 B2Board of Regents, The University of Texas System · 2015